Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
149.5 USD | -0.95% | -1.11% | -21.87% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 19.09B |
---|---|---|---|---|---|
Net income 2024 * | -451M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.52 x |
Net cash position 2024 * | 1.26B | Net cash position 2025 * | 475M | EV / Sales 2025 * | 8.24 x |
P/E ratio 2024 * |
-42.7
x | P/E ratio 2025 * |
-81
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | -1.10% | ||
1 week | -1.11% | ||
Current month | +3.89% | ||
1 month | +2.38% | ||
3 months | -5.14% | ||
6 months | -8.21% | ||
Current year | -21.87% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | 0.00% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 149.5 | -0.90% | 63 834 |
24-05-22 | 150.9 | +0.86% | 350,723 |
24-05-21 | 149.6 | -0.41% | 448,620 |
24-05-20 | 150.2 | +0.56% | 368,554 |
24-05-17 | 149.4 | -1.20% | 481,247 |
Delayed Quote Nasdaq, May 23, 2024 at 10:48 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.87% | 19.09B | |
+63.19% | 62.59B | |
-2.45% | 41.18B | |
+44.13% | 40.29B | |
-8.29% | 27.9B | |
+11.74% | 26.21B | |
+4.72% | 13.08B | |
+24.81% | 12.26B | |
+28.30% | 12.05B | |
-8.18% | 11.28B |
- Stock Market
- Equities
- ALNY Stock